Literature DB >> 33643908

Radiomics Features Predict Telomerase Reverse Transcriptase Promoter Mutations in World Health Organization Grade II Gliomas via a Machine-Learning Approach.

Shengyu Fang1, Ziwen Fan2, Zhiyan Sun1, Yiming Li2, Xing Liu3, Yuchao Liang2, Yukun Liu2, Chunyao Zhou2, Qiang Zhu2, Hong Zhang2, Tianshi Li2, Shaowu Li4, Tao Jiang1,2, Yinyan Wang1,2, Lei Wang2.   

Abstract

The detection of mutations in telomerase reverse transcriptase promoter (pTERT) is important since preoperative diagnosis of pTERT status helps with evaluating prognosis and determining the surgical strategy. Here, we aimed to establish a radiomics-based machine-learning algorithm and evaluated its performance with regard to the prediction of mutations in pTERT in patients with World Health Organization (WHO) grade II gliomas. In total, 164 patients with WHO grade II gliomas were enrolled in this retrospective study. We extracted a total of 1,293 radiomics features from multi-parametric magnetic resonance imaging scans. Elastic net (used for feature selection) and support vector machine with linear kernel were applied in nested 10-fold cross-validation loops. The predictive model was evaluated by receiver operating characteristic and precision-recall analyses. We performed an unpaired t-test to compare the posterior predictive probabilities among patients with differing pTERT statuses. We selected 12 valuable radiomics features using nested 10-fold cross-validation loops. The area under the curve (AUC) was 0.8446 (95% confidence interval [CI], 0.7735-0.9065) with an optimal summed value of sensitivity of 0.9355 (95% CI, 0.8802-0.9788) and specificity of 0.6197 (95% CI, 0.5071-0.7371). The overall accuracy was 0.7988 (95% CI, 0.7378-0.8598). The F1-score was 0.8406 (95% CI, 0.7684-0.902) with an optimal precision of 0.7632 (95% CI, 0.6818-0.8364) and recall of 0.9355 (95% CI, 0.8802-0.9788). Posterior probabilities of pTERT mutations were significantly different between patients with wild-type and mutant TERT promoters. Our findings suggest that a radiomics analysis with a machine-learning algorithm can be useful for predicting pTERT status in patients with WHO grade II glioma and may aid in glioma management.
Copyright © 2021 Fang, Fan, Sun, Li, Liu, Liang, Liu, Zhou, Zhu, Zhang, Li, Li, Jiang, Wang and Wang.

Entities:  

Keywords:  TERT promoter mutation; low-grade glioma; machine-learning; nested cross-validation; radiomics

Year:  2021        PMID: 33643908      PMCID: PMC7905226          DOI: 10.3389/fonc.2020.606741

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  42 in total

1.  Texture information in run-length matrices.

Authors:  X Tang
Journal:  IEEE Trans Image Process       Date:  1998       Impact factor: 10.856

2.  Tumor border sharpness correlates with HLA-G expression in low-grade gliomas.

Authors:  Yinyan Wang; Xing Fan; Hongming Li; Zhiguo Lin; Hongbo Bao; Shaowu Li; Lei Wang; Tianzi Jiang; Yong Fan; Tao Jiang
Journal:  J Neuroimmunol       Date:  2015-03-03       Impact factor: 3.478

3.  Radiogenomics of lower-grade gliomas: machine learning-based MRI texture analysis for predicting 1p/19q codeletion status.

Authors:  Burak Kocak; Emine Sebnem Durmaz; Ece Ates; Ipek Sel; Saime Turgut Gunes; Ozlem Korkmaz Kaya; Amalya Zeynalova; Ozgur Kilickesmez
Journal:  Eur Radiol       Date:  2019-11-05       Impact factor: 5.315

4.  Mutations in the promoter of the telomerase gene TERT contribute to tumorigenesis by a two-step mechanism.

Authors:  Kunitoshi Chiba; Franziska K Lorbeer; A Hunter Shain; David T McSwiggen; Eva Schruf; Areum Oh; Jekwan Ryu; Xavier Darzacq; Boris C Bastian; Dirk Hockemeyer
Journal:  Science       Date:  2017-08-17       Impact factor: 47.728

5.  Radiomics strategy for glioma grading using texture features from multiparametric MRI.

Authors:  Qiang Tian; Lin-Feng Yan; Xi Zhang; Xin Zhang; Yu-Chuan Hu; Yu Han; Zhi-Cheng Liu; Hai-Yan Nan; Qian Sun; Ying-Zhi Sun; Yang Yang; Ying Yu; Jin Zhang; Bo Hu; Gang Xiao; Ping Chen; Shuai Tian; Jie Xu; Wen Wang; Guang-Bin Cui
Journal:  J Magn Reson Imaging       Date:  2018-03-23       Impact factor: 4.813

6.  Autosomal Dominantly Inherited Alzheimer Disease: Analysis of genetic subgroups by Machine Learning.

Authors:  Diego Castillo-Barnes; Li Su; Javier Ramírez; Diego Salas-Gonzalez; Francisco J Martinez-Murcia; Ignacio A Illan; Fermin Segovia; Andres Ortiz; Carlos Cruchaga; Martin R Farlow; Chengjie Xiong; Neil R Graff-Radford; Peter R Schofield; Colin L Masters; Stephen Salloway; Mathias Jucker; Hiroshi Mori; Johannes Levin; Juan M Gorriz
Journal:  Inf Fusion       Date:  2020-01-07       Impact factor: 12.975

7.  Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors.

Authors:  Jeanette E Eckel-Passow; Daniel H Lachance; Annette M Molinaro; Kyle M Walsh; Paul A Decker; Hugues Sicotte; Melike Pekmezci; Terri Rice; Matt L Kosel; Ivan V Smirnov; Gobinda Sarkar; Alissa A Caron; Thomas M Kollmeyer; Corinne E Praska; Anisha R Chada; Chandralekha Halder; Helen M Hansen; Lucie S McCoy; Paige M Bracci; Roxanne Marshall; Shichun Zheng; Gerald F Reis; Alexander R Pico; Brian P O'Neill; Jan C Buckner; Caterina Giannini; Jason T Huse; Arie Perry; Tarik Tihan; Mitchell S Berger; Susan M Chang; Michael D Prados; Joseph Wiemels; John K Wiencke; Margaret R Wrensch; Robert B Jenkins
Journal:  N Engl J Med       Date:  2015-06-10       Impact factor: 176.079

8.  IDH mutation-specific radiomic signature in lower-grade gliomas.

Authors:  Xing Liu; Yiming Li; Shaowu Li; Xing Fan; Zhiyan Sun; Zhengyi Yang; Kai Wang; Zhong Zhang; Tao Jiang; Yong Liu; Lei Wang; Yinyan Wang
Journal:  Aging (Albany NY)       Date:  2019-01-29       Impact factor: 5.682

9.  Radiomics: Images Are More than Pictures, They Are Data.

Authors:  Robert J Gillies; Paul E Kinahan; Hedvig Hricak
Journal:  Radiology       Date:  2015-11-18       Impact factor: 11.105

10.  Prediction of IDH and TERT promoter mutations in low-grade glioma from magnetic resonance images using a convolutional neural network.

Authors:  Ryohei Fukuma; Takufumi Yanagisawa; Manabu Kinoshita; Takashi Shinozaki; Hideyuki Arita; Atsushi Kawaguchi; Masamichi Takahashi; Yoshitaka Narita; Yuzo Terakawa; Naohiro Tsuyuguchi; Yoshiko Okita; Masahiro Nonaka; Shusuke Moriuchi; Masatoshi Takagaki; Yasunori Fujimoto; Junya Fukai; Shuichi Izumoto; Kenichi Ishibashi; Yoshikazu Nakajima; Tomoko Shofuda; Daisuke Kanematsu; Ema Yoshioka; Yoshinori Kodama; Masayuki Mano; Kanji Mori; Koichi Ichimura; Yonehiro Kanemura; Haruhiko Kishima
Journal:  Sci Rep       Date:  2019-12-30       Impact factor: 4.379

View more
  5 in total

Review 1.  A Survey of Radiomics in Precision Diagnosis and Treatment of Adult Gliomas.

Authors:  Peng Du; Hongyi Chen; Kun Lv; Daoying Geng
Journal:  J Clin Med       Date:  2022-06-30       Impact factor: 4.964

Review 2.  Preoperative Diagnosis and Molecular Characterization of Gliomas With Liquid Biopsy and Radiogenomics.

Authors:  Carmen Balana; Sara Castañer; Cristina Carrato; Teresa Moran; Assumpció Lopez-Paradís; Marta Domenech; Ainhoa Hernandez; Josep Puig
Journal:  Front Neurol       Date:  2022-05-26       Impact factor: 4.086

3.  Exploring MRI Characteristics of Brain Diffuse Midline Gliomas With the H3 K27M Mutation Using Radiomics.

Authors:  Qian Li; Fei Dong; Biao Jiang; Minming Zhang
Journal:  Front Oncol       Date:  2021-05-24       Impact factor: 6.244

4.  Prediction of TERTp-mutation status in IDH-wildtype high-grade gliomas using pre-treatment dynamic [18F]FET PET radiomics.

Authors:  Zhicong Li; Lena Kaiser; Adrien Holzgreve; Viktoria C Ruf; Bogdana Suchorska; Vera Wenter; Stefanie Quach; Jochen Herms; Peter Bartenstein; Jörg-Christian Tonn; Marcus Unterrainer; Nathalie L Albert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-09-07       Impact factor: 9.236

Review 5.  Tumor Progression and Treatment-Related Changes: Radiological Diagnosis Challenges for the Evaluation of Post Treated Glioma.

Authors:  Danlei Qin; Guoqiang Yang; Hui Jing; Yan Tan; Bin Zhao; Hui Zhang
Journal:  Cancers (Basel)       Date:  2022-08-03       Impact factor: 6.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.